Table I.

Patient characteristics and frequency of MT2-MMP and HIF-1α expression in pancreatic cancer.

		MT2-MMP			HIF-1α
Variables	Total, n (%)	Negative, n (%)	Positive, n (%)	P-value	Negative, n (%)	Positive, n (%)	P-value
Age at surgery, years				0.598			0.237
<60	46 (59)	20 (44)	26 (56)		22 (48)	24 (52)
≥60	32 (41)	12 (38)	20 (62)		11 (34)	21 (66)
Gender				0.251			0.656
Male	45 (58)	16 (36)	29 (64)		20 (44)	25 (56)
Female	33 (42)	16 (49)	17 (51)		13 (40)	20 (60)
Tumor location				0.475			0.686
Head	50 (64)	22 (44)	28(56)		22 (44)	28 (56)
Body and tail	28 (36)	10 (36)	18 (64)		11 (39)	17 (61)
Tumor size, cm				0.233			0.174
<2	50 (64)	23 (46)	27 (54)		24 (48)	26 (52)
≥2	28 (36)	9 (32)	19 (68)		9 (32)	19 (68)
Perineural invasion				0.475			0.174
Absent	50 (64)	22 (44)	28 (56)		24 (48)	26 (52)
Present	28 (36)	10 (36)	18 (64)		9 (32)	19 (68)
Vascular invasion				0.208			0.052
Absent	63 (81)	28 (44)	35 (56)		30 (48)	33 (52)
Present	15 (19)	4 (27)	11 (74)		3 (20)	12 (80)
Lymph node status				0.673			0.359
Absent	54 (69)	23 (43)	31 (57)		21 (39)	33 (61)
Present	24 (31)	9 (38)	15 (62)		12 (50)	12 (50)
Distant metastasis				0.944			0.399
Absent	68 (87)	28 (41)	40 (59)		30 (44)	38 (56)
Present	10 (13)	4 (40)	6 (60)		3 (30)	7 (70)
TNM stage				0.536			0.538
I+II	48 (62)	21 (44)	27 (56)		19 (40)	29 (60)
III+IV	30 (38)	11 (37)	19 (63)		14 (47)	16 (53)
Cell differentiation				0.251			0.061
I+II	33 (42)	16 (48)	17 (52)		18 (54)	15 (46)
III+IV	45 (58)	16 (36)	29 (64)		15 (33)	30 (67)
Total no. of patients	78 (100)	32 (41)	46 (59)		33 (42)	45 (58)

MT2-MMP, membrane type-2 matrix metalloproteinase; HIF-1α, hypoxia-inducible factor-1α.